The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I study of the oral Notch inhibitor LY900009 in patients with advanced cancer.
Shubham Pant
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Carla Kurkjian
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Kathleen N. Moore
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
D. Scott McMeekin
No relevant relationships to disclose
Jonathan D. Kursar
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Maciej Zamek-Gliszczynski
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Emma Jones
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Eunice Yuen
Employment or Leadership Position - Lilly
Edward Michael Chan
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Johanna C. Bendell
No relevant relationships to disclose